Cancer of unknown primary during pregnancy: An exceptionally rare coexistence
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Peccatori, Fedro A. | en |
dc.contributor.author | Lofts, F. | en |
dc.contributor.author | Greco, F. A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Peccatori, Fedro A. | en |
dc.creator | Lofts, F. | en |
dc.creator | Greco, F. A. | en |
dc.date.accessioned | 2018-06-22T09:54:20Z | |
dc.date.available | 2018-06-22T09:54:20Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42311 | |
dc.description.abstract | Background: Cancer in pregnancy is a rare disease with breast cancer, cervical cancer, melanoma and Hodgkin's disease to be the most commonly diagnosed malignancies during gestation. Cancer of unknown primary (CUP) is a wellrecognized clinical disorder where the primary site can not be identified after a standard diagnostic approach. CUP in pregnancy has rarely been described. Materials and Methods: We searched MEDLINE and contacted cancer Centers in Europe, United States and Australia where patients with CUP or pregnant patients with cancer were diagnosed and treated. Results: Since 1976 we identified 18 pregnant women with CUP in a median gestational age of 34 weeks. Most of these patients were diagnosed with poorly-differentiated histology, had poor response to systemic treatment and a median maternal survival of 8 months. Seventy-two percent of mothers have died, while 80% of the newborns were alive and healthy. Almost one fourth of placentas examined showed metastatic disease. Conclusion: CUP during pregnancy is a very rare coexistence, usually has an aggressive disease with poor response to chemotherapy and a dismal prognosis. Both obstetricians and oncologists should be aware of this rare condition. | en |
dc.language.iso | eng | en |
dc.source | Anticancer Research | en |
dc.subject | Review | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Cancer patient | en |
dc.subject | Female | en |
dc.subject | Cancer survival | en |
dc.subject | Clinical article | en |
dc.subject | Gemcitabine | en |
dc.subject | Taxane derivative | en |
dc.subject | Human tissue | en |
dc.subject | Platinum | en |
dc.subject | Prognosis | en |
dc.subject | Cytoreductive surgery | en |
dc.subject | Survival rate | en |
dc.subject | Treatment outcome | en |
dc.subject | Metastasis | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy | en |
dc.subject | Pregnancy complications | en |
dc.subject | Pregnant woman | en |
dc.subject | Systemic therapy | en |
dc.subject | Cancer prognosis | en |
dc.subject | Bone metastasis | en |
dc.subject | Trastuzumab | en |
dc.subject | Mortality | en |
dc.subject | Histopathology | en |
dc.subject | Laparotomy | en |
dc.subject | Cancer center | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Medline | en |
dc.subject | Adrenal metastasis | en |
dc.subject | Gestational age | en |
dc.subject | Liver metastasis | en |
dc.subject | Lung metastasis | en |
dc.subject | Treatment | en |
dc.subject | Article | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Breast metastasis | en |
dc.subject | Peritoneum metastasis | en |
dc.subject | Placenta | en |
dc.subject | Bladder metastasis | en |
dc.subject | Bone marrow metastasis | en |
dc.subject | Central nervous system metastasis | en |
dc.subject | Diaphragm metastasis | en |
dc.subject | Heart metastasis | en |
dc.subject | Intestine metastasis | en |
dc.subject | Live birth | en |
dc.subject | Muscle metastasis | en |
dc.subject | Pelvis metastasis | en |
dc.subject | Placental in-vasion | en |
dc.subject | Spleen metastasis | en |
dc.subject | Surgical technique | en |
dc.subject | Vemurafenib | en |
dc.title | Cancer of unknown primary during pregnancy: An exceptionally rare coexistence | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 35 | |
dc.description.issue | 1 | |
dc.description.startingpage | 575 | |
dc.description.endingpage | 580 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Peccatori, Fedro A. [0000-0001-8227-8740] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0001-8227-8740 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |